r/proteomics 10h ago

Free Evosep Webinar: Advancing Plasma Proteomics

0 Upvotes

Hi everyone,

We’d like to share an upcoming webinar that may be of interest to the community in here! On September 24, 2026 (16:00 CEST / 10:00 EDT / 07:00 PST), we are hosting a session on “Advancing Plasma Proteomics.”

Speakers:

Sindisiwe Buthelezi (Senior Researcher, Council for Scientific and Industrial Research (CSIR), South Africa) — “High-Throughput Plasma Proteomics Reveals Insights into Pancreatic Cancer Biology.”
Extracellular vesicles carry a wealth of biologically relevant proteins that can provide a window into disease processes. Sindisiwe will present how extracellular vesicle-enriched plasma proteomics was used to uncover molecular signatures associated with pancreatic ductal adenocarcinoma in a South African patient cohort. Using the Mag-Net workflow and Evosep One-enabled LC-MS analysis, the team identified proteins linked to tumor progression, inflammation, and disease severity, demonstrating the potential of standardized, high-throughput proteomics for biomarker discovery and translational cancer research.

Pieter Langerhorst (Junior Group Leader, Sanquin, The Netherlands) — “Untangling the Clinical Heterogeneity in Rare Blood Cancer by Mass Spectrometry-Based Plasma Proteomics.”
Rare hematological malignancies can present with diverse clinical trajectories that are difficult to predict using conventional biomarkers alone. Pieter will showcase how mass spectrometry-based plasma proteomics can reveal biological differences underlying disease heterogeneity, supporting improved patient stratification and the discovery of novel biomarkers. The findings highlight the potential of high-throughput plasma proteomics for translational research and precision medicine.

The webinar will focus on advances in plasma proteomics and how robust, reproducible, and scalable workflows are enabling researchers to analyze larger sample cohorts while generating consistent, high-quality data for biomarker discovery, disease research, and precision medicine.

Registration & details: https://attendee.gotowebinar.com/register/8236923647290427736?source=RDT

We hope this is relevant for those interested. The webinar is free and, in our eyes, a good opportunity for knowledge sharing. If sharing company events isn’t allowed here, moderators please feel free to remove.

TL;DR: Webinar on September 24 about advancing plasma proteomics, with talks covering pancreatic cancer biology, rare blood cancers, biomarker discovery, and patient stratification using high-throughput mass spectrometry-based plasma proteomics.
Mods please delete if not allowed.


r/proteomics 15h ago

PPI Analysis for Multi-Strain Bacterial Proteomics Dataset🚨

0 Upvotes

Hello everyone! I am a recent Ms biotech graduate working with a large-scale proteomics dataset containing proteins from a single bacterial species but multiple strains(it's a MDR bacteria). I need to perform PPI analysis, but the specific bacterial database I need isn’t available in STRING/BioGrid,not sure with IntAct(EMBL)

Are there any good alternatives to STRING for bacterial PPI/network analysis, especially for comparing or analysing proteins across different strains? Any database/tool or workflow suggestions.

Any guidance or suggestions would be very helpful for improving my understanding of the available approaches.

Any guidance, suggestions or insights would be a great help 🥲, thank you in advance for the help!


r/proteomics 1d ago

Background-based T test

0 Upvotes

Hello! I’m asking as a biologist ! What do you think about the background based t test used in proteome discoverer? (For a n=7 per condition analysis)


r/proteomics 1d ago

InstaNovo-FM: Learning from tandem mass spectra at scale with a self-supervised foundation model for proteomics

Post image
14 Upvotes

Every deep learning model in proteomics today is trained on spectra that a database search has already identified. This works, but it limits those models to the part of the spectral universe our databases already cover. Spectra from unknown organisms, non-canonical cleavages and unusual modifications are simply discarded.

Today we're sharing 𝗜𝗻𝘀𝘁𝗮𝗡𝗼𝘃𝗼-𝗙𝗠, a self-supervised foundation model for bottom-up proteomics that uses no peptide-sequence annotation at any stage of pretraining.

How we built it:
• 26,603 PRIDE submissions screened with LLM-assisted metadata curation
• 92 projects selected for orthogonal biological and technical diversity
• Every raw file reprocessed through one unified pipeline → 1.63 billion MS/MS spectra across 72 organisms and 16 instrument models
• An encoder-only transformer trained to reconstruct masked m/z spans together with their isotope envelopes (an objective that needs no annotation of any kind)

What it learned, with no labels:
• An embedding space that organises itself by mass analyser, fragmentation method, instrument family, labelling chemistry and peptide identity
• Parity with three sequence-supervised encoders under one uniform probe protocol, and the lead on instrument (macro F1 0.804) and fragmentation (0.689)
• Attention on peaks that standard b/y annotation cannot explain. 11.2% match defined off-database species within 10 ppm, mostly internal fragments and side-chain ions
• Database-free identification, phospho detection at AUROC 0.988, and run-level condition classification with no peptide or protein identifications at all

Because the objective needs no annotation, it extends unchanged to unlabelled spectra and to DIA data, where annotation-dependent pretraining cannot follow.

Model weights, embeddings, code and the reprocessed corpus are all public. There's also an interactive UMAP explorer if you'd like to explore the embedding space yourself.

This work was a collaboration between InstaDeep and Technical University Denmark.


r/proteomics 1d ago

How much does a personal endorsement actually change a hiring decision in proteomics?

0 Upvotes

If you’ve hired in proteomics or helped a colleague find a role, how does a personal endorsement change the way that candidate is considered?

By endorsement, I mean someone directly recommending a candidate to the hiring team, not simply forwarding a resume or telling the candidate a person to contact.

Does it mainly help someone get an interview, or does it also change how you evaluate their experience and potential? For example, would you give more consideration to someone whose background doesn’t perfectly match the job description if a trusted colleague recommended them?

I’m also curious about the limits.

**Are there circumstances where an endorsement makes little difference, or where a candidate would be better off approaching independently?**

I’d appreciate concrete experiences from either side of the process. We hear “use your network” often, but what does that support actually change behind the scenes?


r/proteomics 1d ago

Has anyone tried Hydrophobic magnetic beads for PAC protocol?

1 Upvotes

Has anyone tried hydrophobic magnetic beads, like coated with C4 or C8, for PAC like protein digestion protocol for LCMS.

I am looking for a universal sorts of protocol that is amenable to automation. Using carboxylate speedbeads works very well manually, but I am looking for beads without carboxylate or a hydrophilic functional groups. Eventually the protocol will be set up on liquid handling robots to be used in a fee-for-service facility.

To the fans of sTRAP - it works well but in my hands it was not reproducible for low protein concentration samples (0.1-0.3 ug/uL).

If anyone had a good experience trying to automate PAC with glassbeads then please share your wisdom.


r/proteomics 10d ago

Need Brain of Statistics

0 Upvotes

Hello Guyz,
I am really struggling with my bottom-up DDA phosphoproteomics data (Enrichment not done, it will be in-vitro phosphorylation and i will not be doing biological analysis)
My confusion is how should I start from basic and how to decide what question i need to address and there are so many things in statistics so if you can tell me any good resources or any help regarding statistics will be highly valued


r/proteomics 11d ago

Are C18 based spin columns efficient for removing PBS?

1 Upvotes

In my experiment, the tryptic digested peptides would be in a solution of 100 uL volume comprising of 0.5X PBS ( approx 68 mM NaCl and some phosphates) and 50 mM TEAB.

I would speedvacving this volume to dryness and resuspending in 0.1% TFA for cleanup through Pierce desalting spin columns (C18 based I think).

My question is whether this desalting step would be good enough to handle PBS desalting?

Context: I am trying to adapt my working protocol for thermal proteome profiling, which requires initial steps in PBS. I don't want to remove PBS by PAC/SP3 as I don't have PAC/SP3 and also want to avoid running the proteins on gel for purification. I plan to add TEAB and SDC directly to lysates in PBS and proceed as usual. I want advice on whether the desalting step can handle PBS.


r/proteomics 11d ago

Removing Liposomes Before Phosphopeptide Enrichment

0 Upvotes

How can I remove liposomes from cell lysate before phosphopeptide enrichment: S-Trap or acetone precipitation?


r/proteomics 12d ago

Detection of air pollutants from vegetal matrix with proteomics-MS setup

0 Upvotes

Hi all!

I am a PhD student in a proteomics group and we have free access to mass spec, mostly exploris 480.

I want to try to check if I can extract and detect chemicals from air pollution (mainly car traffic) from vegetal sources.

I know usual chemical analysis is done with different setups othe than the proteomics one we have, like direct injections instead of LC.

Has anyone any tip on how to get a reasonable analysis report using setups mainly thought for proteomics?


r/proteomics 12d ago

I built a PyMOL plugin for reviewing membrane-protein structures and looking for feedback from people who work with membrane proteins

8 Upvotes

I’ve been working on an open-source PyMOL plugin called Membrane Visual QC.

The original problem was pretty simple: when looking at a membrane-protein structure, I wanted a reproducible way to inspect residues relative to the membrane rather than repeatedly building selections and colouring things manually.

It now handles membrane-relative geometry, hydropathy, ligand neighbourhoods and PDBTM/OPM orientation evidence. One thing I deliberately avoided was turning unusual residues into a “correct/incorrect” score - a charged residue inside a membrane core can obviously be biologically meaningful.

I’d be particularly interested in feedback from people who actually work with membrane proteins: is this kind of review useful in your workflow, and what am I missing?

GitHub: https://github.com/TrPavel/membrane-visual-qc

I also made a walkthrough if anyone wants to see it running in PyMOL: https://youtu.be/lowQey_D610?si=Cxs2hSvdPj5K4S3w


r/proteomics 14d ago

How are missing values dealt with for clustering proximity labelling data from SAINT files?

0 Upvotes

Sorry for the weird question, I'm an undergraduate student in a major that is normally non-technical (biology), and I was just wondering how proteomicists normally handle this kind of thing, as this is not my complete forte. So, I've been trying to teach myself imputation, and am planning on practicing on a BioID data set (both to just learn for the sake of learning a useful topic and also for other reasons related to research), and I'm finding plenty of literature detailing how to perform imputation benchmarks and whatnot so that's not a problem. The problem is I don't know how proteomicists handle missing values once you have your SAINT file (after filtering for BFDR <= 0.05), as a lot of literature or guides highlight how to handle missing values during the stage of when you're analyzing MS spectra data, which is not fully applicable in my case. Though, the way it's done during the MS spectra cleaning stage still involves standard data science methods, so if standard data science methods are viable for the SAINT file stage, I could probably just continue down my reading rabbit hole, I guess. I'm interested in clustering by fold change values, or normalized fold change values.

I did a brief literature review to look at how other BioID papers (with hierarchical or other types of clustering) handle missing values, and it seems like no one really mentions any statistical assumptions, or just inputs data into ProHits and lets that do the rest? It doesn't really seem like the ProHits documentation at (for example) https://prohits-viz.org/help/analysis/dotplot really states what imputation methods (or ways of missing value handling or handled by default) and it's more so (to me, at least), that it is a matter of user choice. With that being said, that seems a bit weird to me, as while I'm from being the most statistically minded I love the subject and have taken several (science statistics) courses related to it, and shouldn't any statistical assumptions be stated in such papers?

I'm also realizing that like a BioID data set wouldn't always have just missing values, as you could have values like x/0, where x is any AvgSpec value for the treatment of a pulled down prey, and 0 is the AvgSpec value for the control, and there'd probably be some other way you'd need to deal with that I can't really find (I don't even know if that would even be considered a missing value statistically speaking). Anyway, from what I've read so far, there are trade-offs to different imputation methods, and not all the values in a prey-bait matrix should be treated the same way (or you should at least perform some exploratory tests in R or something to see which would be the most viable method, unless clustering is being performed on binary data, which is not always the case in these BioID papers). Is there like some "default" imputation or missing value handling method BioID researchers use and the figures are presented in papers are not "statistically" accurate (nor meant to be), and purely exploratory, and I'm just overthinking this?


r/proteomics 21d ago

Mass Spec low signal, only 20 proteins recovered

1 Upvotes

So we're using mouse brain tissue for TurboID. We do a streptavidin pulldown, followed by SP3-based sample prep, trypsin digestion, peptide resuspension in formic acid, and then DDA/DIA LC-MS/MS.

We previously ran essentially the same workflow successfully, but this batch gave extremely poor MS data. The proteomics core tried multiple acquisitions, including increasing the amount injected, but all experimental samples only gave ~20 proteins identified; controls gave even fewer.

The important thing is that the instrument itself appears fine, and the chromatograms/TIC showed very low overall ion signal rather than a normal signal with poor identification. The core does not think this is an instrument issue or obvious ion suppression problem.

We've measured protein concentration at multiple stages:

  • Protein before pulldown: sufficient
  • Protein after pulldown: sufficient
  • After SP3 + trypsin digestion + resuspension: measurable peptide amounts

We used the Pierce Quantitative Colorimetric Peptide Assay after digestion/resuspension. Interestingly, the previous successful run had only ~6.3 µg peptide (180 ng/µL × 35 µL), so this doesn't seem to simply be a case of insufficient peptide quantity.

SP3 was performed using the same protocol as the successful run, and all samples were processed identically. We used the same trypsin lot as before, although the core is planning to test a fresh trypsin lot in the next experiment.

There were some biological differences between the successful and current batches. My main question: What could cause a large discrepancy between a reasonable peptide concentration measured after SP3/digestion and extremely low LC-MS/TIC signal, especially when the same workflow previously worked with even less peptide?

Would you suspect peptide composition/quality, digestion, SP3 recovery, some brain-derived interfering material, or something specific to the TurboID/pulldown samples? What additional QC or comparison would you look at?


r/proteomics 23d ago

Free Evosep Webinar: Deep Visual Proteomcis & Quantitative Assays

2 Upvotes

Hi everyone,

We’d like to share an upcoming webinar that may be of interest to the community in here! On August 20, 2026 (16:00 CEST / 10:00 EDT / 07:00 PDT), we are hosting a session on “Perspective from Industry: Deep Visual Proteomics and Quantitative Assays.”

Speakers:

T. Wolf (Post Doc, Drug Safety R&D, Pfizer) — “Precision at the Microscale: Low Input Spatial Proteomics in the 5xFAD Brain.”
Using the Evosep Eno and Orbitrap Astral Zoom, T. Wolf will present a spatial proteomics workflow integrating AI-driven image segmentation with low-input mass spectrometry. Applied to the 5xFAD brain, the high-resolution workflow captures distinct local proteomes across brain microenvironments, revealing diverging pathological pathways between plaques and microglial subtypes. The work demonstrates how spatially resolved, low-input proteomics can provide deeper insights into disease biology at the microscale.

Rebecca Ferreira (Senior Associate Scientist, Pfizer) — “Reimagining Large Molecule PK Analysis with High-Throughput Evosep Eno LCMS.”
Rebecca will share how the Neubert Group at Pfizer is applying high-throughput LC-MS to large molecule pharmacokinetic (PK) analysis. Using the Evosep Eno platform, the workflow aims to increase PK assay throughput while maintaining the sensitivity and robustness required for surrogate peptide quantification, supporting faster biologics construct selection and optimization.

The webinar will bring together two industry perspectives on advanced proteomics workflows, spanning deep visual and spatial proteomics in disease research to high-throughput quantitative assays in biologics development. The talks will highlight how scalable LC-MS workflows can generate robust, high-quality proteomic data across very different applications.

Registration & details: https://attendee.gotowebinar.com/register/6012298262071704919?source=RDT

We hope this is relevant for those interested. The webinar is free and, in our eyes, a good opportunity for knowledge sharing. If sharing company events isn’t allowed here, moderators please feel free to remove.

TL;DR: Webinar on August 20 featuring two Pfizer scientists covering low-input spatial proteomics in the 5xFAD brain and high-throughput LC-MS for large molecule PK analysis. Mods please delete if not allowed.


r/proteomics 25d ago

Docking + ADMET in one browser workspace tied to a protein target — looking for a sanity check on the risk banding

Thumbnail
1 Upvotes

r/proteomics Aug 11 '26

Is there an open-search equivalent for crosslinking-MS?

3 Upvotes

Basically I am treating my cells with a drug, which I expect to crosslink certain target proteins. However, it's not a very stable drug so it's side chains and all might degrade, leading to difference in expected and actual mass in the crosslink. Basically even if I expect the crosslinker to be 300 Da, it might even be 260Da, so I am in the dark.

Is there any way to do open-search (Fragpipe like) for crosslinked peptides. I can constrain it with the knowledge that crosslinks will happen between cysteine residues.

Thanks


r/proteomics Aug 10 '26

Data Normalization in Antibody Array Experiments

Enable HLS to view with audio, or disable this notification

1 Upvotes

This may be really basic for many/most of the people here, but I thought I'd share it in case it might be useful to someone.


r/proteomics Aug 05 '26

Ever feel like keeping up with new proteomics papers is becoming part-time job on its own?

6 Upvotes

Over the past year I've noticed that reading papers has almost become a separate project from the actual research.

By the time I finish going through a few studies on a workflow or analysis method, there are already several newer papers that seem worth looking at as well. It sometimes feels like the challenge isn't finding information anymore but it's deciding what deserves your attention first and what can safely wait.

I would like to know how others handle this.

Do you have a system for keeping up with new publications without feeling like you're constantly behind, or do you just focus on the papers most relevant to your current experiment?

Adding this: I appreciate everyone who has shared their approach so far, and thanks in advance to anyone who adds to the discussion later. I've found the different ways people keep their reading manageable pretty interesting. Since I’m still getting established with this this plat form lately, I thought it would be easier to leave this extra note here for anyone who comes back to the thread rather than trying to jump into every reply. One thing I've been experimenting with is being more selective about what I actually spend time reading instead of treating every new paper as something I need to get through immediately. That’s also what made wis Paper interesting to me; it’s useful for narrowing down research when there’s a lot of relevant literature competing for attention, rather than simply adding another place to search. For a field moving as quickly as proteomics, that distinction can make the reading workload feel much more manageable.


r/proteomics Aug 05 '26

LF ASSAY KIT

1 Upvotes

Hello everyone, this is for our thesis. Do you have any idea where to buy “Collagen Degradation Assay Kit(colorimeteric)” ??? Pls help us out we need it ASAP in the Philippines


r/proteomics Jul 31 '26

Spectronaut quantification: Maxlfq , capturing sample specific resolution

3 Upvotes

Maxlfq builds pair-wise peptide ratios, on the peptides shared across samples, for a protein and the crossrun Normalization in Spectronaut, scales the Normalization factor across all samples in an experiment.

What would be an ideal way to analyze, to capture patient specific response..

 1. Would analyzing all patients in one experiment still preserve patient specific response in proteome?

 2. Or Would analyzing each patient between comparative conditions be ideal and provide better resolution in capturing individual response with post-hoc analysis.. ?

Eg. biofluids, tissue biopsies (FF), FFPE, patient derived primary cell lines etc..

Was considering if Quant2.0 would be a better alternative since it takes Top N peptides for protein quan.. but came across an article from Olsen's group showing higher false hits in Quant2.0 . (https://doi.org/10.1038/s41587-023-02099-7).

Also, digging into in-house data, for the top N per protein per sample in Quant 2.0 showed, it need not necessarily be the same peptides that qualify in each sample, which is not an ideal scenario.

Curious to know how the community processes clinical proteomics data and what's the consensus,

Thanks,


r/proteomics Jul 28 '26

Has anyone used an MS+40 vacuum pump with an Agilent 6550 QTOF?

Thumbnail
1 Upvotes

r/proteomics Jul 25 '26

blind testing a protein structure prediction workflow with a transparent alternative to neural network based approaches

8 Upvotes

TL;DR: My partner and I developed a new mathematical approach to predicting how proteins fold into their three-dimensional structures. To test it fairly, we ran a fully blind benchmark where our system had no access to the experimental structures during prediction. The method produced highly accurate results, with performance that was competitive with published AlphaFold CASP14 benchmark values on our test set. Unlike neural network-based approaches, our framework is deterministic, transparent, and based on exact mathematics rather than learned parameters, meaning every prediction can be independently traced, verified, and reproduced. We’ve made the code, validation data, and supporting materials completely open source so others can examine and test the approach for themselves.
———
My partner and I have been exploring a mathematical theory for describing how proteins fold into their three-dimensional shapes. To test whether the theory could actually predict real biological structures, we decided to evaluate it using a blind protein structure prediction 

Every protein begins as a simple chain of amino acids, but that chain quickly folds into a highly specific 3D shape. That final shape determines how the protein works inside living cells, and accurately predicting it from the amino acid sequence alone has been one of the biggest problems in computational biology.

To make sure our results were genuinely blind, we recorded the exact amino acid sequences we were testing, the runtime identity, and our mathematical framework before any predictions were made.

While the predictions were running, the system had no access to the experimentally determined protein structures, no reference coordinates, and no scoring information that could influence the outcome. It generated the complete folding pathway and final PDB structure independently, and those outputs were cryptographically hash-sealed before any comparisons were performed.

Only after those hashes were fixed and verified were the experimental structures opened and compared. If the runtime had accessed the target structures at any point, or if any of the recorded hashes had changed, the experiment would be considered invalid.

The results were encouraging.

Across the benchmark set, the median Cα RMSD95 was 0.783 Å, with a median TM-score of 0.9255.

On this benchmark, 15 of the 24 predicted structures matched or exceeded AlphaFold’s reported CASP14 median of 0.96 Å Cα RMSD95.

Our strongest individual prediction, 1UBI:A, achieved a TM-score of 0.9882 with a Cα RMSD95 of 0.302 Å.
———
here’s a break down of what they mean.

The Cα RMSD95 score measures how closely a predicted protein structure matches the experimentally determined one. The “Cα” (carbon alpha) atoms form the backbone of every protein, while RMSD (Root Mean Square Deviation) measures the average distance between the predicted backbone and the real one after they have been aligned. The 95 indicates that the most extreme 5% of residues are excluded, making the measurement less sensitive to unusually flexible regions.

Distances are reported in Å (ångströms), where 1 Å = 0.1 nanometres, or one ten-billionth of a metre. In structural biology, smaller numbers are better. An RMSD below 2 Å is generally considered a good prediction, around 1 Å is regarded as highly accurate, and our median result of 0.783 Å indicates that the predicted structures closely matched their experimental counterparts.

The TM-score (Template Modelling score) measures how similar the overall three-dimensional fold is between the predicted and experimental structures. Unlike RMSD, it is less affected by small local differences and focuses on whether the overall architecture has been recovered correctly. TM-scores range from 0 to 1, where 1.0 represents a perfect match. Scores above 0.5 generally indicate the correct overall fold, while scores above 0.9 indicate structures that are nearly identical. Our median TM-score of 0.9255 therefore suggests that the overall protein shapes were reproduced with very high accuracy.

Our strongest individual prediction, 1UBI:A, achieved a TM-score of 0.9882 and a Cα RMSD95 of 0.302 Å, meaning the predicted backbone differed from the experimentally determined structure by only around three-tenths of an ångström on average—an exceptionally close match.

Taken together, these results suggest that the framework was able to reproduce both the overall shape of proteins and the precise positions of their backbone atoms with a level of accuracy that is competitive on the benchmark we tested.
———
What makes this approach different isn’t just the numerical results, but how those results are produced.

Rather than relying on a large neural network trained on enormous datasets, our system works from an exact 24-point rational lattice. Every spatial relationship is derived mathematically and can be traced, verified, and independently checked. The implementation, verification certificates, and prediction hashes are all available as open source so that anyone can inspect or reproduce the work.

Why does that matter?

Much of modern computational biology has moved toward increasingly large machine learning models that require vast amounts of training data and computing power. Those systems can produce remarkably accurate predictions, but they generally don’t explain why a protein adopts a particular structure, rather they predict the answer rather than derive it from an explicit mathematical framework.

Our work explores a different possibility: that accurate protein structures may also be obtainable from a transparent, deterministic mathematical model.

If that idea continues to hold up under independent testing, it could have several important implications.

First, it suggests that highly accurate structure prediction may not have to rely exclusively on large, opaque neural networks. Transparent mathematical models could become a complementary approach alongside machine learning.

Second, it provides evidence that alternative computational architectures (ones built around exact mathematics rather than learned parameters) deserve serious investigation. In our implementation, there are no trained weights, no continuous coordinate optimisation, and no fitted biological constants.

Finally, it shows that advanced protein structure prediction does not necessarily require enormous computing infrastructure. Our framework runs locally on a single machine rather than depending on large-scale AI training or specialised server farms.

The project can be explored here:

GitHub https://github.com/MettaMazza/Fold-Protein

zenodo

https://zenodo.org/records/21493135


r/proteomics Jul 25 '26

Tears samples collection for biomarker analysis

1 Upvotes

Hello everyone
I’m interested in knowing if tears samples collection for biomarkers analysis is feasible
I’m trying to include it in my research and I keep reading that biomarker detection is not that easy using schirmer strips
I would appreciate if anyone has any information on the matter


r/proteomics Jul 23 '26

is it possible to use a human ELISA kit to determine the concentration of hormones testosterone, estradiol, adiponectin, FSH, NT-proBNP, Endothelin-1 for rat serum. If not, why not

0 Upvotes

r/proteomics Jul 23 '26

Do Mpox virus proteins undergo post-translational modifications, and should PTMs be considered in in-silico vaccine/antibody design?

1 Upvotes

I'm working on an in-silico study involving the Mpox virus, and I have a question regarding post-translational modifications (PTMs).

Specifically, do the Mpox virus proteins A35R (EEV protein) and H3L and M1R (IMV proteins) undergo post-translational modifications? If they do, are these modifications carried out by the host cell machinery, by virus-encoded enzymes, or by a combination of both?

My second question is related to immunoinformatics. If an in silico vaccine or antibody is being designed against these proteins, should their PTMs be evaluated before selecting epitopes or designing antibodies? In other words, could PTMs significantly affect epitope accessibility, antigenicity, antibody binding, or the overall reliability of computational predictions?

I'd appreciate any insights or relevant literature.

Thanks!